141W94/ VX-478, oral HIV protease inhibitor: Phase II Update

The compound is being developed with Glaxo and Kissei

Read the full 97 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE